Private company

Oncternal Therapeutics, Inc.

American pharmaceutical preparations company based in Memphis.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersMemphis, United States
Incorporated inDE²
Business address12230 El Camino Real, Suite 230, San Diego, Ca 92130²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-5313.9%Operating margin³

-5029.2%Net margin³

-47.3%Revenue growth, 2023³

-131.4%Return on equity³

Where the money goes

Where each dollar of revenue went, fiscal 2023

Other costs

Other costs100¢$785.0K

Out of $785.0K in revenue.³ The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷³$785.0K in 2023−69% since 2018

Operating income⁸⁴⁵⁶⁷³-$41.7M in 2023+36% since 2017

Net income⁸⁴⁵⁶⁷³-$39.5M in 2023+30% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Revenue		$2.5M⁴	$2.4M⁵	$3.4M⁶	$4.3M⁷	$1.5M³	$785.0K³
Research and development		$0⁴	$0⁵	$0⁶	$0⁷	$0⁷
Operating income	-$30.7M⁸	-$7.6M⁴	-$33.1M⁵	-$17.5M⁶	-$31.4M⁷	-$44.9M³	-$41.7M³
Interest		$1.0K⁴
Income tax					$0⁷	$0³	$0³
Net income	-$30.4M⁸	-$6.6M⁴	-$34.2M⁵	-$17.2M⁶	-$31.3M⁷	-$44.2M³	-$39.5M³
Earnings per share	-$1.75¹²				-$0.64⁷	-$16.80³	-$13.43³
Earnings per share (diluted)	-$1.75¹²				-$0.64⁷	-$16.80³	-$13.43³

Total assets⁸⁴⁵⁶⁷³$36.7M in 2023−21% since 2017

Total liabilities³$6.7M in 2023−13% since 2022

Shareholders’ equity⁴⁵⁶⁷³$30.1M in 2023

Cash⁸⁴⁵⁶⁷³$6.7M in 2023−58% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash	$15.8M⁸	$20.6M⁴	$20.1M⁵	$116.7M⁶	$90.8M⁷	$37.1M³	$6.7M³
Current assets	$46.1M⁸	$21.2M⁴	$20.8M⁵	$118.0M⁶	$92.9M⁷	$67.3M³	$36.1M³
Total assets	$46.2M⁸	$22.0M⁴	$21.7M⁵	$118.8M⁶	$93.6M⁷	$68.7M³	$36.7M³
Current liabilities	$8.0M⁸	$4.3M⁴	$7.3M⁵	$5.9M⁶	$5.5M⁷	$7.7M³	$5.2M³
Total liabilities						$7.7M³	$6.7M³
Shareholders’ equity	-$23.3M⁴	-$29.6M⁵	$14.3M⁶	$113.0M⁷	$88.1M³	$61.0M³	$30.1M³
Shares outstanding	21.5M shares⁸	3.8M shares⁴	15.4M shares⁵	48.8M shares⁶	49.4M shares⁷	2.9M shares³	2.9M shares³

Cash from operations⁸⁴⁵⁶⁷³-$32.2M in 2023+37% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash from operations	-$23.5M⁸	-$7.4M⁴	-$16.7M⁵	-$17.5M⁶	-$26.6M⁷	-$36.7M³	-$32.2M³
Capital spending	$2.0K⁸
Free cash flow	-$23.5M

Compare Oncternal Therapeutics, Inc. with another company

Leadership

Who has led Oncternal Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Robert James Wills2015–2018

President

Chief financial officer

Chief operating officer

Marc Steven Hanover2007–2014

2010201520202025

Chief executive officerJames B. Breitmeyer Jun 11, 2019 to Feb 15, 2024¹³
Chief executive officerMarc Steven Hanover Apr 7, 2014 to Jan 9, 2018¹⁴
Chief executive officerMitchell Shuster Steiner Mar 13, 2006 to Jan 31, 2014¹⁵
ChairRobert James Wills Mar 4, 2015 to Jun 26, 2018¹⁶
PresidentJames B. Breitmeyer Jun 11, 2019 to Jun 20, 2019¹³
PresidentMarc Steven Hanover Feb 8, 2007 to Nov 18, 2014¹⁷
Chief financial officerRichard G. Vincent Jun 11, 2019 to Feb 15, 2024¹⁸
Chief financial officerMark Edward Mosteller May 15, 2006 to Jul 10, 2013¹⁹
Chief operating officerMarc Steven Hanover Feb 8, 2007 to Nov 18, 2014¹⁷

Board members and other officers (42)

Chief Medical OfficerSalim Yazji May 27, 2021 to Feb 15, 2024²⁰
Chief Medical OfficerFrank J. Hsu Aug 28, 2019 to Jul 31, 2020²¹
Chief Scientific OfficerGunnar F. Kaufmann Sep 9, 2019 to Jun 14, 2023²²
Chief Business OfficerIgor Bilinsky Sep 9, 2019 to Feb 16, 2021²³
Legal CounselHazel M. Aker Sep 16, 2019 to Jul 31, 2020²⁴
VP, Chief Medical OfficerDiane C. Young Jul 15, 2015 to Jul 17, 2018²⁵
Principal Accounting OfficerJason T. Shackelford Dec 30, 2013 to Jun 22, 2018²⁶
Vice President - SalesChristopher K. West Jan 8, 2008 to Aug 4, 2008²⁷
Vice PresidentDomingo Rodriguez May 5, 2008 to Aug 4, 2008²⁸
Vice PresidentShontelle Dodson May 5, 2008 to Aug 4, 2008²⁹
VP, Chief Medical OfficerRonald A. Morton Jr. May 3, 2007 to Jan 4, 2012³⁰
Vice President, RegulatoryJeffrey G. Hesselberg May 16, 2007 to Aug 4, 2008³¹
Vice PresidentGregory A. Deener Jan 4, 2006 to Jan 4, 2011³²
Vice PresidentJames T. Dalton Jan 4, 2006 to Jul 3, 2014³³
Vice PresidentK. Gary Barnette Jan 4, 2006 to Aug 4, 2008³⁴
Vice President and SecretaryHenry Patton Doggrell May 15, 2006 to Jan 3, 2013³⁵
Board memberJill Desimone Jan 5, 2023 to Jun 24, 2024³⁶
Board memberCharles Theuer Jun 11, 2019 to Jun 24, 2024³⁷
Board memberDaniel L. Kisner Jun 11, 2019 to Jun 24, 2024³⁸
Board memberDavid F. Hale Jun 11, 2019 to Jun 24, 2024³⁹
Board memberJames B. Breitmeyer Jun 11, 2019 to Feb 15, 2024¹³
Board memberWilliam R. Larue Jun 11, 2019 to Jun 24, 2024⁴⁰
Board memberXin Nakanishi Jun 11, 2019 to Jun 30, 2023⁴¹
Board memberRobert James Wills Sep 16, 2019 to Jun 24, 2024⁴²
Board memberMan Cho Dec 23, 2019 to Jul 31, 2020⁴³
Board memberGarry Arthur Neil Sep 1, 2016 to Jan 3, 2019⁴⁴
Board memberJack W. Schuler Mar 5, 2012 to Mar 5, 2012⁴⁵
Board memberBarry J. A. Furr Jan 4, 2011 to Jan 6, 2015⁴⁶
Board memberKenneth S. Robinson May 5, 2008 to Oct 2, 2018⁴⁷
Board memberMarc Steven Hanover Feb 8, 2007 to Jan 9, 2018¹⁷
Board memberAndrew M. Clarkson Jan 4, 2006 to Jul 2, 2008⁴⁸
Board memberJ. Kenneth Glass Jan 4, 2006 to May 11, 2018⁴⁹
Board memberJohn Hofmann Pontius Jan 4, 2006 to Jul 5, 2011⁵⁰
Board memberJoseph R. Hyde Iii. Jan 4, 2006 to Jan 3, 2019⁵¹
Board memberRobert W. Karr Jan 4, 2006 to May 4, 2010⁵²
Board memberRosemary Mazanet Jan 4, 2006 to Jun 24, 2024⁵³
Board memberTimothy R. G. Sear Jan 4, 2006 to Jan 3, 2013⁵⁴
Board memberMitchell Shuster Steiner Mar 13, 2006 to Jan 31, 2014¹⁵
Board memberMichael G. Carter May 11, 2006 to Jun 24, 2024⁵⁵
General counselChase C. Leavitt May 27, 2021 to Feb 15, 2024⁵⁶
General counselHazel M. Aker Jun 11, 2019 to Jun 11, 2019⁵⁷
General counselHenry Patton Doggrell Oct 2, 2013 to Jun 22, 2018⁵⁸

Former names

GTX INC /DE/Jan 30, 2004 to Jun 11, 2019²
GTX INC/TNAug 21, 2003 to Jan 15, 2004²

Timeline

Jun 11, 2019New chief executive James B. Breitmeyer becomes CEO¹³
Apr 7, 2014New chief executive Marc Steven Hanover becomes CEO¹⁴
Mar 13, 2006New chief executive Mitchell Shuster Steiner becomes CEO¹⁵
Sep 4, 2003Founded Oncternal Therapeutics, Inc. is founded⁵⁹

Filings

190 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 38 major events, 93 insider forms, 3 large holders, 42 other. The latest 20:

The 190 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 3 such filings since October 2021:

Feb 13, 2024SC 13G/A
Jul 8, 2022SC 13G
Feb 4, 2022SC 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAROncternal Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGAROncternal Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGAROncternal Therapeutics, Inc. 10-K for fiscal 2023
4
SEC EDGAROncternal Therapeutics, Inc. 10-K for fiscal 2018
5
SEC EDGAROncternal Therapeutics, Inc. 10-K for fiscal 2019
6
SEC EDGAROncternal Therapeutics, Inc. 10-K for fiscal 2020
7
SEC EDGAROncternal Therapeutics, Inc. 10-K for fiscal 2021
8
SEC EDGAROncternal Therapeutics, Inc. 10-K for fiscal 2017
9
SEC EDGAROncternal Therapeutics, Inc. 10-Q for fiscal 2024
10
SEC EDGAROncternal Therapeutics, Inc. 10-Q for fiscal 2024
11
SEC EDGAROncternal Therapeutics, Inc. 10-Q for fiscal 2024
12
SEC EDGAROncternal Therapeutics, Inc. 10-K for fiscal 2017
13
SEC EDGARJames B. Breitmeyer, Chief executive officer
14
SEC EDGARMarc Steven Hanover, Chief executive officer
15
SEC EDGARMitchell Shuster Steiner, Chief executive officer
16
SEC EDGARRobert James Wills, Chair
17
SEC EDGARMarc Steven Hanover, President
18
SEC EDGARRichard G. Vincent, Chief financial officer
19
SEC EDGARMark Edward Mosteller, Chief financial officer
20
SEC EDGARSalim Yazji, Chief Medical Officer
21
SEC EDGARFrank J. Hsu, Chief Medical Officer
22
SEC EDGARGunnar F. Kaufmann, Chief Scientific Officer
23
SEC EDGARIgor Bilinsky, Chief Business Officer
24
SEC EDGARHazel M. Aker, Legal Counsel
25
SEC EDGARDiane C. Young, VP, Chief Medical Officer
26
SEC EDGARJason T. Shackelford, Principal Accounting Officer
27
SEC EDGARChristopher K. West, Vice President - Sales
28
SEC EDGARDomingo Rodriguez, Vice President
29
SEC EDGARShontelle Dodson, Vice President
30
SEC EDGARRonald A. Morton Jr., VP, Chief Medical Officer
31
SEC EDGARJeffrey G. Hesselberg, Vice President, Regulatory
32
SEC EDGARGregory A. Deener, Vice President
33
SEC EDGARJames T. Dalton, Vice President
34
SEC EDGARK. Gary Barnette, Vice President
35
SEC EDGARHenry Patton Doggrell, Vice President and Secretary
36
SEC EDGARJill Desimone, Board member
37
SEC EDGARCharles Theuer, Board member
38
SEC EDGARDaniel L. Kisner, Board member
39
SEC EDGARDavid F. Hale, Board member
40
SEC EDGARWilliam R. Larue, Board member
41
SEC EDGARXin Nakanishi, Board member
42
SEC EDGARRobert James Wills, Board member
43
SEC EDGARMan Cho, Board member
44
SEC EDGARGarry Arthur Neil, Board member
45
SEC EDGARJack W. Schuler, Board member
46
SEC EDGARBarry J. A. Furr, Board member
47
SEC EDGARKenneth S. Robinson, Board member
48
SEC EDGARAndrew M. Clarkson, Board member
49
SEC EDGARJ. Kenneth Glass, Board member
50
SEC EDGARJohn Hofmann Pontius, Board member
51
SEC EDGARJoseph R. Hyde Iii., Board member
52
SEC EDGARRobert W. Karr, Board member
53
SEC EDGARRosemary Mazanet, Board member
54
SEC EDGARTimothy R. G. Sear, Board member
55
SEC EDGARMichael G. Carter, Board member
56
SEC EDGARChase C. Leavitt, General counsel
57
SEC EDGARHazel M. Aker, General counsel
58
SEC EDGARHenry Patton Doggrell, General counsel
59
gleifOncternal Therapeutics, Inc. is founded